Genomic Expression Inc. has developed the OneRNA® platform, a cutting-edge technology that leverages RNA analysis to enhance cancer treatment and drug development. This platform allows for the repurposing of approved drugs tailored to individual patients, significantly improving the precision of cancer therapies. Unlike traditional DNA panels that analyze a limited number of genes, the OneRNA® platform examines over 20,000 mRNA transcripts, providing a comprehensive view of the tumor's molecular landscape. This extensive analysis not only aids in monitoring health and detecting diseases but also facilitates the rapid translation of RNA code into novel RNA therapeutics, thereby individualizing treatment plans for patients with breast and ovarian cancer.

The OneRNA® platform is designed to streamline the clinical development process by transforming companion diagnostics into algorithms, which can dramatically reduce costs and risks associated with drug approvals. By utilizing a single biomarker approach, the platform enhances patient enrollment in clinical studies, addressing a common challenge in oncology research. Furthermore, the technology is adaptable and scalable, making it applicable across various diseases beyond cancer. Genomic Expression Inc. aims to pioneer the future of personalized medicine by developing next-generation RNA therapeutics that can be manufactured quickly, ultimately improving patient outcomes and advancing the field of genomics.

United States

Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression's  OneRNA™ test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA's to approved therapies and clinical trials.

Genomic Expression Inc

Company Details